Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.

Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S.

Mod Pathol. 2019 Sep 30. doi: 10.1038/s41379-019-0371-0. [Epub ahead of print]

PMID:
31570769
2.

Age over 50 years is not a contraindication for anterior cruciate ligament reconstruction.

Costa GG, Grassi A, Perelli S, Agrò G, Bozzi F, Lo Presti M, Zaffagnini S.

Knee Surg Sports Traumatol Arthrosc. 2019 Apr 3. doi: 10.1007/s00167-019-05450-1. [Epub ahead of print]

PMID:
30944945
3.

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C.

J Immunol Res. 2018 Oct 29;2018:5804230. doi: 10.1155/2018/5804230. eCollection 2018.

4.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A.

Mol Cancer Ther. 2018 Mar;17(3):603-613. doi: 10.1158/1535-7163.MCT-17-0324. Epub 2017 Dec 13.

5.

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production.

Mogavero A, Maiorana MV, Zanutto S, Varinelli L, Bozzi F, Belfiore A, Volpi CC, Gloghini A, Pierotti MA, Gariboldi M.

Sci Rep. 2017 Nov 22;7(1):15992. doi: 10.1038/s41598-017-16149-z.

6.

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Bosotti R, Magnaghi P, Di Bella S, Cozzi L, Cusi C, Bozzi F, Beltrami N, Carapezza G, Ballinari D, Amboldi N, Lupi R, Somaschini A, Raddrizzani L, Salom B, Galvani A, Stacchiotti S, Tamborini E, Isacchi A.

Sci Rep. 2017 Aug 23;7(1):9226. doi: 10.1038/s41598-017-10044-3.

7.

New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs).

Negri T, Brich S, Bozzi F, Volpi CV, Gualeni AV, Stacchiotti S, De Cecco L, Canevari S, Gloghini A, Pilotti S.

Oncotarget. 2017 May 16;8(20):32492-32504. doi: 10.18632/oncotarget.16477.

8.

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini CM, D'Incalci M, Gatta R.

BMC Cancer. 2017 Feb 6;17(1):107. doi: 10.1186/s12885-017-3091-1.

9.

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Bozzi F, Mogavero A, Varinelli L, Belfiore A, Manenti G, Caccia C, Volpi CC, Beznoussenko GV, Milione M, Leoni V, Gloghini A, Mironov AA, Leo E, Pilotti S, Pierotti MA, Bongarzone I, Gariboldi M.

J Exp Clin Cancer Res. 2017 Jan 23;36(1):16. doi: 10.1186/s13046-016-0475-z.

10.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S.

Oncotarget. 2016 Nov 15;7(46):75503-75517. doi: 10.18632/oncotarget.12262.

11.

Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.

Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gualeni AV, Gloghini A, Stacchiotti S, Pierotti MA, Pilotti S, Negri T.

Oncotarget. 2016 Jul 19;7(29):45015-45026. doi: 10.18632/oncotarget.7523.

12.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S.

Oncotarget. 2014 Aug 15;5(15):5965-77.

13.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.

Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G.

Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19.

14.

[The safety profile of escitalopram in pregnancy and breastfeeding].

Bellantuono C, Orsolini L, Bozzi F.

Riv Psichiatr. 2013 Nov-Dec;48(6):407-14. doi: 10.1708/1379.15335. Review. Italian.

PMID:
24441517
15.

Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.

Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, Gronchi A, Panizza P, Pierotti MA, Tamborini E, Pilotti S.

Neuro Oncol. 2014 Jan;16(1):72-80. doi: 10.1093/neuonc/not238.

16.

Safety of escitalopram in pregnancy: a case series.

Bellantuono C, Bozzi F, Orsolini L.

Neuropsychiatr Dis Treat. 2013;9:1333-7. doi: 10.2147/NDT.S45951. Epub 2013 Sep 9.

17.

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.

Lab Invest. 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9.

18.

Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.

Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG.

Clin Cancer Res. 2013 Sep 15;19(18):5192-201. doi: 10.1158/1078-0432.CCR-13-0776. Epub 2013 Jul 25.

19.

Phase II study on lapatinib in advanced EGFR-positive chordoma.

Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, Casali PG.

Ann Oncol. 2013 Jul;24(7):1931-6. doi: 10.1093/annonc/mdt117. Epub 2013 Apr 4.

PMID:
23559153
20.

The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review.

Bellantuono C, Bozzi F, Orsolini L, Catena-Dell'Osso M.

Hum Psychopharmacol. 2012 Nov;27(6):534-9. doi: 10.1002/hup.2265. Epub 2012 Oct 9. Review.

PMID:
23044635
21.

The CD133 expression levels and its role as potential cancer stem cells marker in gastrointestinal stromal tumor.

Bozzi F, Tamborini E, Pilotti S.

Int J Cancer. 2012 Sep 1;131(5):E849-50. doi: 10.1002/ijc.27374. Epub 2012 Feb 18. No abstract available.

22.

Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.

Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S.

Genes Chromosomes Cancer. 2012 Feb;51(2):111-26. doi: 10.1002/gcc.20933. Epub 2011 Nov 1.

PMID:
22045652
23.

Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.

Da Riva L, Bozzi F, Mondellini P, Miccichè F, Fumagalli E, Vaghi E, Tarantino E, Huber V, Gronchi A, Tamborini E, Pierotti MA, Pilotti S, Bongarzone I.

J Transl Med. 2011 Sep 23;9:158. doi: 10.1186/1479-5876-9-158.

24.

High CD133 expression levels in gastrointestinal stromal tumors.

Bozzi F, Conca E, Manenti G, Negri T, Brich S, Gronchi A, Pierotti MA, Tamborini E, Pilotti S.

Cytometry B Clin Cytom. 2011 Jul-Aug;80(4):238-47. doi: 10.1002/cyto.b.20589. Epub 2011 Apr 1.

25.

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S.

Ann Oncol. 2011 Jul;22(7):1682-90. doi: 10.1093/annonc/mdq644. Epub 2011 Jan 17.

PMID:
21242589
26.

Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.

Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, Jocollè G, Cassinelli G, Grosso F, Sanfilippo R, Casalini P, Greco A, Pierotti MA, Pilotti S.

Clin Cancer Res. 2010 Jul 15;16(14):3581-93. doi: 10.1158/1078-0432.CCR-09-2912. Epub 2010 Jun 3.

27.

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.

Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R.

Cancer Res. 2009 Sep 15;69(18):7338-46. doi: 10.1158/0008-5472.CAN-08-4419. Epub 2009 Sep 1.

28.

Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).

Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S.

J Pathol. 2009 Jan;217(1):103-12. doi: 10.1002/path.2450.

PMID:
18973210
29.

Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.

Bozzi F, Ferrari A, Negri T, Conca E, Luca da R, Losa M, Casieri P, Orsenigo M, Lampis A, Meazza C, Casanova M, Pierotti MA, Tamborini E, Pilotti S.

Transl Oncol. 2008 Jul;1(2):95-101.

30.

Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma.

Bozzi F, Collini P, Aiello A, Barzanò E, Gambirasio F, Podda M, Meazza C, Ferrari A, Luksch R.

Anticancer Res. 2008 May-Jun;28(3A):1565-9.

31.

Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion.

Schiavo R, Tullio C, La Grotteria M, Andreotti IC, Scarpati B, Romiti L, Bozzi F, Pedrazzoli P, Siena S.

Anticancer Res. 2007 Sep-Oct;27(5A):3273-8.

32.

Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.

Bozzi F, Tamborini E, Negri T, Pastore E, Ferrari A, Luksch R, Casanova M, Pierotti MA, Bellani FF, Pilotti S.

Cancer. 2007 Apr 15;109(8):1638-45.

33.

Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.

Bozzi F, Gambirasio F, Luksch R, Collini P, Brando B, Fossati-Bellani F.

Anticancer Res. 2006 Sep-Oct;26(5A):3281-7.

34.

Peripheral blood stem cell collection in pediatric patients: feasibility of leukapheresis under anesthesia in uncompliant small children with solid tumors.

Ravagnani F, Coluccia P, Notti P, Arienti F, Bompadre A, Avella M, Bozzi F, Barzanò E, Podda M, Pupa S, Luksch R.

J Clin Apher. 2006 Jul;21(2):85-91.

PMID:
16035098
35.

Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.

Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R, Collini P, Massimino M, Cefalo G, Terenziani M, Ferrari A, Casanova M, Spreafico F, Meazza C, Bozzi F, Marchianò A, Ravagnani F, Fossati-Bellani F.

Br J Cancer. 2005 Jun 6;92(11):1984-8.

36.

Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.

Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F.

Neuro Oncol. 2005 Jan;7(1):41-8.

37.

Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.

Bozzi F, Luksch R, Collini P, Gambirasio F, Barzanò E, Polastri D, Podda M, Brando B, Fossati-Bellani F.

Diagn Mol Pathol. 2004 Sep;13(3):135-43.

PMID:
15322424
38.

Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma.

Luksch R, Perotti D, Cefalo G, Gambacorti Passerini C, Massimino M, Spreafico F, Casanova M, Ferrari A, Terenziani M, Polastri D, Gambirasio F, Podda M, Bozzi F, Ravagnani F, Parmiani G, Fossati Bellani F.

Tumori. 2003 May-Jun;89(3):263-8.

PMID:
12908780
39.

V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations.

Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG, Arkwright PD, Baniyash M, Brooks EG, Conley ME, Cortes P, Duse M, Fasth A, Filipovich AM, Infante AJ, Jones A, Mazzolari E, Muller SM, Pasic S, Rechavi G, Sacco MG, Santagata S, Schroeder ML, Seger R, Strina D, Ugazio A, Väliaho J, Vihinen M, Vogler LB, Ochs H, Vezzoni P, Friedrich W, Schwarz K.

Blood. 2001 Jan 1;97(1):81-8.

PMID:
11133745
40.

N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains.

Santagata S, Gomez CA, Sobacchi C, Bozzi F, Abinun M, Pasic S, Cortes P, Vezzoni P, Villa A.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14572-7.

41.

Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies.

Gomez CA, Ptaszek LM, Villa A, Bozzi F, Sobacchi C, Brooks EG, Notarangelo LD, Spanopoulou E, Pan ZQ, Vezzoni P, Cortes P, Santagata S.

Mol Cell Biol. 2000 Aug;20(15):5653-64.

42.

Prenatal diagnosis of RAG-deficient Omenn syndrome.

Villa A, Bozzi F, Sobacchi C, Strina D, Fasth A, Pasic S, Notarangelo LD, Vezzoni P.

Prenat Diagn. 2000 Jan;20(1):56-9.

PMID:
10701853
43.

The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombination.

Santagata S, Besmer E, Villa A, Bozzi F, Allingham JS, Sobacchi C, Haniford DB, Vezzoni P, Nussenzweig MC, Pan ZQ, Cortes P.

Mol Cell. 1999 Dec;4(6):935-47.

44.

Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome.

Signorini S, Imberti L, Pirovano S, Villa A, Facchetti F, Ungari M, Bozzi F, Albertini A, Ugazio AG, Vezzoni P, Notarangelo LD.

Blood. 1999 Nov 15;94(10):3468-78.

PMID:
10552957
45.

Omenn syndrome: a disorder of Rag1 and Rag2 genes.

Villa A, Santagata S, Bozzi F, Imberti L, Notarangelo LD.

J Clin Immunol. 1999 Mar;19(2):87-97. Review.

PMID:
10226883
46.

Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment.

Bozzi F, Lefranc G, Villa A, Badolato R, Schumacher RF, Khalil G, Loiselet J, Bresciani S, O'Shea JJ, Vezzoni P, Notarangelo LD, Candotti F.

Br J Haematol. 1998 Sep;102(5):1363-6.

PMID:
9753072
47.

Partial V(D)J recombination activity leads to Omenn syndrome.

Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, Gatta LB, Ochs HD, Schwarz K, Notarangelo LD, Vezzoni P, Spanopoulou E.

Cell. 1998 May 29;93(5):885-96.

48.

Structural and functional basis for JAK3-deficient severe combined immunodeficiency.

Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P, Fiorini M, Ugazio AG, Badolato R, Notarangelo LD, Bozzi F, Macchi P, Strina D, Vezzoni P, Blaese RM, O'Shea JJ, Villa A.

Blood. 1997 Nov 15;90(10):3996-4003.

PMID:
9354668
49.

The exon-intron structure of human LHX1 gene.

Bozzi F, Bertuzzi S, Strina D, Giannetto C, Vezzoni P, Villa A.

Biochem Biophys Res Commun. 1996 Dec 13;229(2):494-7.

PMID:
8954926
50.

The ZNF75 zinc finger gene subfamily: isolation and mapping of the four members in humans and great apes.

Villa A, Strina D, Frattini A, Faranda S, Macchi P, Finelli P, Bozzi F, Susani L, Archidiacono N, Rocchi M, Vezzoni P.

Genomics. 1996 Jul 15;35(2):312-20.

PMID:
8661144

Supplemental Content

Support Center